TRIPARTITE COOPERATION AGREEMENT By and Between NOVARTIS PHARMA AG GENENTECH, INC. AND TANOX, INC. Dated as of February 25, 2004Tripartite Cooperation Agreement • May 10th, 2004 • Tanox Inc • Pharmaceutical preparations • New York
AMENDED AND RESTATED DEVELOPMENT AND LICENSING AGREEMENTDevelopment and Licensing Agreement • May 10th, 2004 • Tanox Inc • Pharmaceutical preparations • New York
This Amended and Restated Development and Licensing Agreement (“Agreement”) is made and entered into as of the 25th day of February, 2004 (the “Effective Date”), between Tanox, Inc. (formerly known as Tanox Biosystems, Inc.), originally a Texas corporation and reincorporated as a Delaware corporation (“Tanox”), and Novartis Pharma AG, a company organized and existing under the laws of Switzerland (as successor-in-interest of Ciba-Geigy Limited) (“Novartis”). (Each of Novartis and Tanox is referred to herein individually as a “Party” and all are referred to collectively herein as the “Parties.”)
ANCILLARY DEVELOPMENT & LICENSING AGREEMENT By and Between NOVARTIS PHARMA AG AND TANOX, INC. Dated as of February 25, 2004Licensing Agreement • May 10th, 2004 • Tanox Inc • Pharmaceutical preparations • New York
AMENDMENT NO. 1 TO SETTLEMENT AND CROSS-LICENSE AGREEMENT-License Agreement • May 10th, 2004 • Tanox Inc • Pharmaceutical preparations • New York
This Amendment (“Amendment”), effective as of February 25, 2004 (the “Amendment Effective Date”) is made by and between Genentech, Inc. (“Genentech”), a Delaware corporation having a principal place of business at 1 DNA Way, South San Francisco, California 94080, and Tanox, Inc. (formerly known as Tanox Biosystems, Inc.), originally a Texas corporation and reincorporated as a Delaware corporation (“Tanox”), with its principal offices at 10301 Stella Link, Houston, Texas 77025.
